Supernus Pharmaceuticals, Inc. (SUPN) Financials

Key financial figures for Supernus Pharmaceuticals, Inc. (Q2 2026).

Revenue

$219M

Net Income

-$58M

EPS

$-1.01

Total Assets

$1.4B

Operating Cash Flow

-$5M

Full income statement, balance sheet, and cash flow for Supernus Pharmaceuticals, Inc. on SentiSense.